Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION Trial: Pegaptanib Sodium in Wet AMD
NCT00321997Phase 3Completed
- Sponsor
- OSI Eyetech
- Start
- May 2001
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
01
Overview
A Phase 3 trial of pegaptanib sodium in exudative age-related macular degeneration, sponsored by OSI Eyetech. Started May 2001; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00321997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321997.